China 67630-00-6 Tert-butoxycarbonyl-4-NO2-phenylalanine-ethyl ester Manufacturer and Factory |Jiayinglai

67630-00-6 Tert-butoxycarbonyl-4-NO2-phenylalanine-ethyl ester

Description:

Aspectus	Album ad Off-Crystallis alba vel crystallina pulveris.
MF	C16H22N2O6
MW	338.36
Puritas	98+

Mitte ad nos inscriptio

Product Detail

Transportatio conditio & commendatur naviculas modum:
per aerem, per mare vel per express

Repono conditione:
Signatum in siccis, cella Temperature

Ordinis Qty minimum:
Negatio

Certification:
COA, HPLC, GC, HNMR, Assay, Aqua Content (KF), TLC available

Synonyma

(S)-ethyl 2-(tert-butoxycarbonylaMino) -3-(4-nitrophenyl) propanoate;
Boc-(4-NO2)-L-Phe-OEt;
Boc- (4-NO2)-Oet;
Boc-Phe(4-NO2)-Oet;
L-Phenylalanine;
N.

interiorem sarcina

Solent ad stipant pulveris.Et soles et aqua possunt prohibere mala questus.

exteriores sarcina

Lobortis duris res tuas ex fragore et umore questus protegere potest.

Applications

Nidanib, chemica est.Nomen chemicum 1 h - indole 6 - acidi carboxylici, 2, 3 - dihydro- 3 - [[[4 - (methyl. - 2 - oxygenii -, methyl ester, (z) -. Hoc productum adhibetur fibrosis pulmonis idiopathici tractare (IPF).
Nidanib 1,529 aegros fibrosis pulmonis idiopathici (IPF) in multiplicibus iudiciis clinicis studuit.Salus data praesentata sunt in comparatione aegrorum 1061 datis nidanib 150 mg bis cotidie et placebo in duabus 52-septimanis 3 hebdomadis, incertis, duplici-caecis, studiis placebo sobriis (INPULSIS-I et INPULSIS-2).Frequentissima res adversae cum usu nidanib inclusa sunt diarrhoea, nausea et vomitus, dolor abdominis, inedia, pondus damnum, et iecur enzymes elevatum.Placere referuntur ad administrationem motus contrarios correspondentes.Organum systematicum Classificationis (SOC) MedDRA summam praebet reactiones adversae et classificationem frequentiam.
Nidanib subiecta est pro P-gp (vide Pharmacokinetica).In speciali studio medicamentorum interactionum, administratio ketoconazoli coniuncta, inhibitoris P-gp potens, expositio nidanib ad 1,61 vicibus per aream curvam (AUC) et 1,83 temporibus per intentionem apicem (Cmax) aucta est.
In pharmaco studio commercii cum potente P-gp inducente rifampicin, detectio nidanib ad 50.3% decrevit, ut area sub curva (AUC) mensurata, cum rifampicin cum sola Nidanib comparata.Per intentionem apicem (Cmax), ad 60,3% decrevit.
Cum in coniunctione cum hoc productum administratum, potentes P-gp inhibitores (exempli gratia ketoconazoli vel erythromycin) augere possunt expositionem nidanib.His in casibus arcte viverra aegri patientia nidanib debet.Procuratio reactionum adversarum requiri potest discontinuationem, reductionem, vel discontinuationem curationis cum hoc productum (videatur usus et dosis).
P-gp potentes inducentes (eg, rifampicin, carbamazepinum, phenytoin et struthio S. Ioannis) possunt reducere expositionem nidanib.Coniunctiones alternativae cum inductione nulla vel minima P-gp considerari debent.

Related Products

Gly-Phe	Boc-Phe-Gly-Ome	HN-Me-L-Phe.Hcl	Boc-D-Phe-D-Phe
Boc-D-4-Chloropheny(alanine)	Fmoc-L-Phe-OH	L-Phe-NH2.Hcl	Boc-Phe-Gly
L-Ala-Phe-OH	Fmoc-D-Phe-OH	4-NO2-Phe-Oet	Boc-L-Phe-Onp
Boc-Ala-Phe-OH	Fmoc-N-Me-L-Phe-OH	4-NO2-Phe-Oet.HCl	Boc-L-Phe-Oet
Boc-Ala-Phe-OH	FMOC-N-Me-D-Phe-OH	HD-Phe-OMe·HCl	Boc-4-NO2-D-Phe-OEt
Fmoc-β-Ala-D-phe	Fmoc-Phe-Cl	HL-Phe-OMe.HCl	Boc-D,L-Phe(4-NO2)-OH
Leu-Phe.Hcl	Fmoc-Phe(4-NO2)-OH	H-DL-Phe-OBzl .tos	Fmoc-Phe-Phe-OH
Boc-Leu-Phe	Cbz-L-Phe-OH	H-DL-Phe(4-NO2)-OH.H2O	Fmoc-Phe-Gly-OH
Cbz-L-Phe-Leu-OH	Cbz-D-Phe-OH	HL-Phe-OBzl.HCl	Fmoc-D-Phe(4-NO2)-OH
L-Phe	Cbz-DL-Phe-OH	HL-Phe-OEt.HCl	Cbz-Phe-Arg-OH
HD-Phe-OH	Cbz-D-Phe-OL	L-Phe-NH2	Cbz-Phe-Ala-OH
L-Phe-NCA	ZN-Me-L-Phe-OH	D-Phe-NH2	Cbz-Phe-Gly-OH
Tos-Phe	cbz-L-Phe-OSU	N-Ac-L-Phe-OH	Cbz-Phe-Met-OH
L-Phe-ol	Phe-Ala	N-AC-L-Phe-Ome	Cbz-Phe-Gly-Oet
L-Phe（4-NO2）-OH	L-Phe-Phe	N-Pht-Phe-OH	Boc-Phe-Gly-Gly-OH
L-Phe（4-NO2）.H2O	L-Phe-Trp	Boc-Phe-OH	Fmoc-L-Thr(tBu)-Phe-OH
D-Phe(4-NO2)-OH.h2o	L-Phe-Leu-OH	Boc-D-Phe-OH	D-Phe-NH2
D-Phe(4-NO2)-OH	L-Phe-Tyr-OH	Boc-DL-Phe-OH	Tyr-Phe
N-Me-D-Phe	L-Phe-Gly	BOC-N-Me-D-Phe-OH	DL-Phe-Ome.Hcl
HN-Me-L-Phe-OH	D-Phe-D-Phe	Boc-N-Me-DL-Phe-OH	Boc-Met-Leu-Phe
L-Phe.hcl	L-Phe-OBzl-OH	Boc-N-Me-L-Phe-OH	Asp-Phe-Ome
4-NO2-D-phe.hcl	D-Phe-Obzl.Tos	Boc-N-Me-L-Phe-OH.DCHA	L-Homophe-OH
HL-Phe-OtBu.HCl	Boc-Phe-Ala-OH	Boc-DN-Me-Phe•DCHA	D-Homophe-OH
HD-Phe-OtBu.HCl	Boc-Phe-Leu-OH	Boc-Phe-Ol	L-Homophe-Oet.Hcl
D,L-Phe-OtBu HCl	Boc-Phe-Trp-OH	Boc-D-Phe-Ol	D-Homophe-Oet.HCl
HD-Phe(4-NO2)-Ome.HCl	Boc-L-Phe-Tyr-OH	Boc-Phe-NH2	Boc-L-Homophe-OH
D-Phe-Obzl.Hcl	Boc-Phe-OH	Boc-L-Phe-Ome	Boc-D-Homophe-OH
DL-Phe-Ome.Hcl	Boc-D-Phe-Phe	Boc-D-Phe-Ome	Fmoc-L-HomoPhe-OH
Boc-D-Phe(4-NO2)-OH	Cbz-D-Homophe-OH	Boc-Phe-Obzl	Fmoc-D-Homophe-OH
Boc-L-Phe-OSU	Boc-Homophe-Leu-Phe-Ome	Boc-4-NO2-Phe-OH	Cbz-L-Homophe-OH
Boc-D-Phe-OSU

Superioritas

1. R & D ministerium praesto
2. ISO fabrica certificata, cautio qualitatis
3.A plena curriculum sequitur opera per productionem
4.High sumptus efficens
5.Quality documenta certificatione provisum est per petitionem elit
6.Great post-venditio muneris arctam necessitudinem cum mos conservans
7.Full resource ad auxilium decrescentes shipping costs
8.Free specimen oblatum Lorem species prior ad mercedem
9.Payment terminus agi
10.Assit customers res in Sina